Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
Allergen-specific immunotherapy has not been well-studied in the setting of increasingly common immune system-targeting medications. Subcutaneous immunotherapy may not be contraindicated in patients taking anti-CD20 mAbs antibodies and/or Janus kinase inhibitors.
Saved in:
Main Authors: | Twan Sia, BA, Leeon Bacchus, BA, Stanley Liu, BS, John Leung, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-05-01
|
Series: | Journal of Allergy and Clinical Immunology: Global |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772829325000128 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
by: Stamatios Gregoriou, et al.
Published: (2025-01-01) -
The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01) -
Response to upadacitinib monotherapy in a patient with eczematid-like pigmented purpuric dermatosis
by: Aditi Chokshi, DO, et al.
Published: (2025-02-01) -
Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis
by: Amy Perrin Ross, et al.
Published: (2025-01-01) -
Refractory Chronic Hand Eczema Responds to Oral Upadacitinib
by: Nada Alghamdi, et al.
Published: (2025-01-01)